{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:46:56Z","timestamp":1794638816718,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-112972RB-I00"],"award-info":[{"award-number":["PID2020-112972RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["202032"],"award-info":[{"award-number":["202032"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["P01 NS097197"],"award-info":[{"award-number":["P01 NS097197"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Biomedicina de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lafora disease (LD; OMIM#254780) is a rare, devastating, and fatal form of progressive myoclonus epilepsy that affects young adolescents and has no treatment yet. One of the hallmarks of the disease is the accumulation of aberrant poorly branched forms of glycogen (polyglucosans, PGs) in the brain and peripheral tissues. The current hypothesis is that this accumulation is causative of the pathophysiology of the disease. Another hallmark of LD is the presence of neuroinflammation. We have recently reported the presence of reactive glia-derived neuroinflammation in LD mouse models and defined the main inflammatory pathways that operate in these mice, mainly TNF and IL-6 signaling pathways. In addition, we described the presence of infiltration of peripheral immune cells in the brain parenchyma, which could cooperate and aggravate the neuroinflammatory landscape of LD. In this work, we have checked the beneficial effect of two compounds with the capacity to ameliorate neuroinflammation and reduce leukocyte infiltration into the brain, namely fingolimod and dimethyl fumarate. Our results indicate a beneficial effect of fingolimod in reducing reactive astrogliosis-derived neuroinflammation and T-lymphocyte infiltration, which correlated with the improved behavioral performance of the treated\n                    <jats:italic>Epm2b-\/-<\/jats:italic>\n                    mice. On the contrary, dimethyl fumarate, although it was able to reduce reactive astrogliosis, was less effective in preventing neuroinflammation and T-lymphocyte infiltration and in modifying behavioral tests.\n                  <\/jats:p>","DOI":"10.1007\/s12035-023-03766-1","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T05:02:43Z","timestamp":1700110963000},"page":"3105-3120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beneficial Effect of Fingolimod in a Lafora Disease Mouse Model by Preventing Reactive Astrogliosis-Derived Neuroinflammation and Brain Infiltration of T-lymphocytes"],"prefix":"10.1007","volume":"61","author":[{"given":"Teresa","family":"Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Campos-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-4103","authenticated-orcid":false,"given":"Pascual","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"1","key":"3766_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13023-021-01989-w","volume":"16","author":"F Pondrelli","year":"2021","unstructured":"Pondrelli F, Muccioli L, Licchetta L, Mostacci B, Zenesini C, Tinuper P, Vignatelli L, Bisulli F (2021) Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis. Orphanet J Rare Dis 16(1):362","journal-title":"Orphanet J Rare Dis"},{"key":"3766_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02863929","volume":"6","author":"GR Lafora","year":"1911","unstructured":"Lafora GR, Glueck B (1911) Beitrag zur histogpathologie der myoklonischen epilepsie. Gesamte Neurol Psychiatr 6:1\u201314","journal-title":"Gesamte Neurol Psychiatr"},{"issue":"2","key":"3766_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1212\/WNL.20.2.160","volume":"20","author":"M Sakai","year":"1970","unstructured":"Sakai M, Austin J, Witmer F, Trueb L (1970) Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20(2):160\u2013176","journal-title":"Neurology"},{"key":"3766_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107975","volume":"119","author":"KH Markussen","year":"2021","unstructured":"Markussen KH, Macedo JKA, Machio M, Dolce A, Goldberg YP, Vander Kooi CW, Gentry MS (2021) The 6th International Lafora Epilepsy Workshop: advances in the search for a cure. Epilepsy Behav 119:107975","journal-title":"Epilepsy Behav"},{"issue":"4","key":"3766_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.neurol.2021.06.006","volume":"178","author":"S Mitra","year":"2022","unstructured":"Mitra S, Gumusgoz E, Minassian BA (2022) Lafora disease: current biology and therapeutic approaches. Rev Neurol (Paris) 178(4):315\u2013325","journal-title":"Rev Neurol (Paris)"},{"issue":"2","key":"3766_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/2470","volume":"20","author":"BA Minassian","year":"1998","unstructured":"Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R et al (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 20(2):171\u2013174","journal-title":"Nat Genet"},{"issue":"2","key":"3766_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ng1238","volume":"35","author":"EM Chan","year":"2003","unstructured":"Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M et al (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35(2):125\u2013127","journal-title":"Nat Genet"},{"issue":"11","key":"3766_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/nn1998","volume":"10","author":"D Vilchez","year":"2007","unstructured":"Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, Criado-Garcia O, Fernandez-Sanchez E et al (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10(11):1407\u20131413","journal-title":"Nat Neurosci"},{"issue":"5","key":"3766_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/hmg\/ddm339","volume":"17","author":"MC Solaz-Fuster","year":"2008","unstructured":"Solaz-Fuster MC, Gimeno-Alcaniz JV, Ros S, Fernandez-Sanchez ME, Garcia-Fojeda B, Criado Garcia O, Vilchez D, Dominguez J et al (2008) Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum Mol Genet 17(5):667\u2013678","journal-title":"Hum Mol Genet"},{"issue":"8","key":"3766_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cells7080087","volume":"7","author":"MA Garcia-Gimeno","year":"2018","unstructured":"Garcia-Gimeno MA, Knecht E, Sanz P (2018) Lafora disease: a ubiquitination-related pathology. Cells 7(8):87","journal-title":"Cells"},{"issue":"10","key":"3766_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","volume":"14","author":"F Nitschke","year":"2018","unstructured":"Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA (2018) Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol 14(10):606\u2013617","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"3766_CR12","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1007\/s12035-016-9884-4","volume":"54","author":"I Lopez-Gonzalez","year":"2017","unstructured":"Lopez-Gonzalez I, Viana R, Sanz P, Ferrer I (2017) Inflammation in Lafora disease: evolution with disease progression in laforin and malin knock-out mouse models. Mol Neurobiol 54(5):3119\u20133130","journal-title":"Mol Neurobiol"},{"issue":"3","key":"3766_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","volume":"57","author":"M Lahuerta","year":"2020","unstructured":"Lahuerta M, Gonzalez D, Aguado C, Fathinajafabadi A, Garcia-Gimenez JL, Moreno-Estelles M, Roma-Mateo C, Knecht E et al (2020) Reactive glia-derived neuroinflammation: a novel hallmark in Lafora progressive myoclonus epilepsy that progresses with age. Mol Neurobiol 57(3):1607\u20131621","journal-title":"Mol Neurobiol"},{"issue":"7","key":"3766_CR14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/hmg\/ddy044","volume":"27","author":"C Rubio-Villena","year":"2018","unstructured":"Rubio-Villena C, Viana R, Bonet J, Garcia-Gimeno MA, Casado M, Heredia M, Sanz P (2018) Astrocytes: new players in progressive myoclonus epilepsy of Lafora type. Hum Mol Genet 27(7):1290\u20131300","journal-title":"Hum Mol Genet"},{"key":"3766_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105964","volume":"176","author":"T Rubio","year":"2023","unstructured":"Rubio T, Viana R, Moreno-Estelles M, Campos-Rodriguez A, Sanz P (2023) TNF and IL6\/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy. Neurobiol Dis 176:105964","journal-title":"Neurobiol Dis"},{"issue":"11","key":"3766_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","volume":"11","author":"S Ganesh","year":"2002","unstructured":"Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, Akagi T, Gomi H et al (2002) Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 11(11):1251\u20131262","journal-title":"Hum Mol Genet"},{"issue":"7","key":"3766_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/hmg\/ddr590","volume":"21","author":"O Criado","year":"2012","unstructured":"Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millan B, Heredia M et al (2012) Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Hum Mol Genet 21(7):1521\u20131533","journal-title":"Hum Mol Genet"},{"issue":"5","key":"3766_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/NEN.0b013e318253350f","volume":"71","author":"AM Garcia-Cabrero","year":"2012","unstructured":"Garcia-Cabrero AM, Marinas A, Guerrero R, de Cordoba SR, Serratosa JM, Sanchez MP (2012) Laforin and malin deletions in mice produce similar neurologic impairments. J Neuropathol Exp Neurol 71(5):413\u2013421","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"3766_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/cne.25006","volume":"529","author":"K Taneja","year":"2021","unstructured":"Taneja K, Ganesh S (2021) Dendritic spine abnormalities correlate with behavioral and cognitive deficits in mouse models of Lafora disease. J Comp Neurol 529(6):1099\u20131120","journal-title":"J Comp Neurol"},{"issue":"6","key":"3766_CR20","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1007\/s12035-021-02285-1","volume":"58","author":"B Molla","year":"2021","unstructured":"Molla B, Heredia M, Sanz P (2021) Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model. Mol Neurobiol 58(6):2508\u20132522","journal-title":"Mol Neurobiol"},{"issue":"10","key":"3766_CR21","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1007\/s12035-022-02956-7","volume":"59","author":"B Molla","year":"2022","unstructured":"Molla B, Heredia M, Campos A, Sanz P (2022) Pharmacological modulation of glutamatergic and neuroinflammatory pathways in a Lafora disease mouse model. Mol Neurobiol 59(10):6018\u20136032","journal-title":"Mol Neurobiol"},{"issue":"13","key":"3766_CR22","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.3390\/cells11132058","volume":"11","author":"GA Bravo","year":"2022","unstructured":"Bravo GA, Cedeno RR, Casadevall MP, Ramio-Torrenta L (2022) Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives. Cells 11(13):2058","journal-title":"Cells"},{"issue":"8","key":"3766_CR23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/antiox9080700","volume":"9","author":"M Rosito","year":"2020","unstructured":"Rosito M, Testi C, Parisi G, Cortese B, Baiocco P, Di Angelantonio S (2020) Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment. Antioxidants (Basel) 9(8):700","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"3766_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/ph14070607","volume":"14","author":"IS Sadovnikova","year":"2021","unstructured":"Sadovnikova IS, Gureev AP, Ignatyeva DA, Gryaznova MV, Chernyshova EV, Krutskikh EP, Novikova AG, Popov VN (2021) Nrf2\/ARE activators improve memory in aged mice via maintaining of mitochondrial quality control of brain and the modulation of gut microbiome. Pharmaceuticals (Basel) 14(7):607","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"3766_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","volume":"145","author":"S Schilling","year":"2006","unstructured":"Schilling S, Goelz S, Linker R, Luehder F, Gold R (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145(1):101\u2013107","journal-title":"Clin Exp Immunol"},{"key":"3766_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mvr.2015.12.003","volume":"105","author":"JL Lim","year":"2016","unstructured":"Lim JL, van der Pol SM, Di Dio F, van Het Hof B, Kooij G, de Vries HE, van Horssen J (2016) Protective effects of monomethyl fumarate at the inflamed blood-brain barrier. Microvasc Res 105:61\u201369","journal-title":"Microvasc Res"},{"issue":"2","key":"3766_CR27","doi-asserted-by":"publisher","first-page":"fcab047","DOI":"10.1093\/braincomms\/fcab047","volume":"3","author":"J Groh","year":"2021","unstructured":"Groh J, Berve K, Martini R (2021) Immune modulation attenuates infantile neuronal ceroid lipofuscinosis in mice before and after disease onset. Brain Commun 3(2):fcab047","journal-title":"Brain Commun"},{"key":"3766_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40268-020-00316-1","volume":"20","author":"P Bascu\u00f1ana","year":"2020","unstructured":"Bascu\u00f1ana P, M\u00f6hle L, Brackhan M, Pahnke J (2020) Fingolimod as a treatment in neurological disorders beyond multiple sclerosis. Drugs R&D 20:197\u2013207","journal-title":"Drugs R&D"},{"issue":"1","key":"3766_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-022-00878-y","volume":"12","author":"SK Vainio","year":"2022","unstructured":"Vainio SK, Dickens AM, Matilainen M, Lopez-Picon FR, Aarnio R, Eskola O, Solin O, Anthony DC et al (2022) Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation. EJNMMI Res 12(1):6","journal-title":"EJNMMI Res"},{"key":"3766_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119852","volume":"283","author":"AR Vanani","year":"2021","unstructured":"Vanani AR, Kalantari H, Mahdavinia M, Rashno M, Khorsandi L, Khodayar MJ (2021) Dimethyl fumarate reduces oxidative stress, inflammation and fat deposition by modulation of Nrf2, SREBP-1c and NF-kappaB signaling in HFD fed mice. Life Sci 283:119852","journal-title":"Life Sci"},{"issue":"1\u20132","key":"3766_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.brainresrev.2011.02.005","volume":"67","author":"R Lalonde","year":"2011","unstructured":"Lalonde R, Strazielle C (2011) Brain regions and genes affecting limb-clasping responses. Brain Res Rev 67(1\u20132):252\u2013259","journal-title":"Brain Res Rev"},{"key":"3766_CR32","first-page":"1787","volume":"39","author":"SJ Guyenet","year":"2010","unstructured":"Guyenet SJ, Furrer SA, Damian VM, Baughan TD, La Spada AR, Garden GA (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp 39:1787","journal-title":"J Vis Exp"},{"key":"3766_CR33","volume":"96","author":"ML Seibenhener","year":"2015","unstructured":"Seibenhener ML, Wooten MC (2015) Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp 96:e52434","journal-title":"J Vis Exp"},{"key":"3766_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pnpbp.2018.05.010","volume":"86","author":"NO Abdel Rasheed","year":"2018","unstructured":"Abdel Rasheed NO, El Sayed NS, El-Khatib AS (2018) Targeting central beta2 receptors ameliorates streptozotocin-induced neuroinflammation via inhibition of glycogen synthase kinase3 pathway in mice. Prog Neuropsychopharmacol Biol Psychiatry 86:65\u201375","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"3766_CR35","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1093\/brain\/awab194","volume":"144","author":"S Ahonen","year":"2021","unstructured":"Ahonen S, Nitschke S, Grossman TR, Kordasiewicz H, Wang P, Zhao X, Guisso DR, Kasiri S et al (2021) Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain 144(10):2985\u20132993","journal-title":"Brain"},{"issue":"3","key":"3766_CR36","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s13311-022-01218-7","volume":"19","author":"E Gumusgoz","year":"2022","unstructured":"Gumusgoz E, Kasiri S, Guisso DR, Wu J, Dear M, Verhalen B, Minassian BA (2022) AAV-mediated artificial miRNA reduces pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models. Neurotherapeutics 19(3):982\u2013993","journal-title":"Neurotherapeutics"},{"issue":"2","key":"3766_CR37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s13311-021-01040-7","volume":"18","author":"E Gumusgoz","year":"2021","unstructured":"Gumusgoz E, Guisso DR, Kasiri S, Wu J, Dear M, Verhalen B, Nitschke S, Mitra S et al (2021) Targeting Gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and Lafora disease mouse models. Neurotherapeutics 18(2):1414\u20131425","journal-title":"Neurotherapeutics"},{"issue":"7","key":"3766_CR38","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1021\/acs.jmedchem.9b01851","volume":"63","author":"B Tang","year":"2020","unstructured":"Tang B, Frasinyuk MS, Chikwana VM, Mahalingan KK, Morgan CA, Segvich DM, Bondarenko SP, Mrug GP et al (2020) Discovery and development of small-molecule inhibitors of glycogen synthase. J Med Chem 63(7):3538\u20133551","journal-title":"J Med Chem"},{"issue":"4","key":"3766_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.cmet.2019.07.002","volume":"30","author":"MK Brewer","year":"2019","unstructured":"Brewer MK, Uittenbogaard A, Austin GL, Segvich DM, DePaoli-Roach A, Roach PJ, McCarthy JJ, Simmons ZR et al (2019) Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion. Cell Metab 30(4):689\u2013705","journal-title":"Cell Metab"},{"issue":"2","key":"3766_CR40","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s12035-015-9091-8","volume":"53","author":"A Berthier","year":"2016","unstructured":"Berthier A, Paya M, Garcia-Cabrero AM, Ballester MI, Heredia M, Serratosa JM, Sanchez MP, Sanz P (2016) Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease. Mol Neurobiol 53(2):1296\u20131309","journal-title":"Mol Neurobiol"},{"issue":"1","key":"3766_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s13311-022-01304-w","volume":"20","author":"DF Burgos","year":"2023","unstructured":"Burgos DF, Machio-Castello M, Iglesias-Cabeza N, Giraldez BG, Gonzalez-Fernandez J, Sanchez-Martin G, Sanchez MP, Serratosa JM (2023) Early treatment with metformin improves neurological outcomes in Lafora disease. Neurotherapeutics 20(1):230\u2013244","journal-title":"Neurotherapeutics"},{"issue":"5","key":"3766_CR42","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/jnc.15685","volume":"162","author":"W Zhang","year":"2022","unstructured":"Zhang W, Li Y, Li F, Ling L (2022) Sphingosine-1-phosphate receptor modulators in stroke treatment. J Neurochem 162(5):390\u2013403","journal-title":"J Neurochem"},{"key":"3766_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neuroscience.2023.03.023","volume":"519","author":"S Hajipour","year":"2023","unstructured":"Hajipour S, Khombi Shooshtari M, Farbood Y, Ali Mard S, Sarkaki A, Moradi Chameh H, Sistani Karampour N, Ghafouri S (2023) Fingolimod administration following hypoxia induced neonatal seizure can restore impaired long-term potentiation and memory performance in adult rats. Neuroscience 519:107\u2013119","journal-title":"Neuroscience"},{"issue":"11","key":"3766_CR44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2174\/1570159X18666200420125017","volume":"18","author":"YN Paudel","year":"2020","unstructured":"Paudel YN, Angelopoulou E, Piperi C, Gnatkovsky V, Othman I, Shaikh MF (2020) From the molecular mechanism to pre-clinical results: anti-epileptic effects of fingolimod. Curr Neuropharmacol 18(11):1126\u20131137","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"3766_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/epi.16450","volume":"61","author":"P Klein","year":"2020","unstructured":"Klein P, Friedman A, Hameed MQ, Kaminski RM, Bar-Klein G, Klitgaard H, Koepp M, Jozwiak S et al (2020) Repurposed molecules for antiepileptogenesis: missing an opportunity to prevent epilepsy? Epilepsia 61(3):359\u2013386","journal-title":"Epilepsia"},{"key":"3766_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.807639","volume":"13","author":"S Pournajaf","year":"2022","unstructured":"Pournajaf S, Dargahi L, Javan M, Pourgholami MH (2022) Molecular pharmacology and novel potential therapeutic applications of fingolimod. Front Pharmacol 13:807639","journal-title":"Front Pharmacol"},{"issue":"8","key":"3766_CR47","first-page":"1763","volume":"18","author":"LX Yang","year":"2023","unstructured":"Yang LX, Yao YY, Yang JR, Cheng HL, Zhu XJ, Zhang ZJ (2023) Sphingosine 1-phosphate receptor 1 regulates blood-brain barrier permeability in epileptic mice. Neural Regen Res 18(8):1763\u20131769","journal-title":"Neural Regen Res"},{"key":"3766_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.brainresbull.2018.11.013","volume":"144","author":"N Singh","year":"2019","unstructured":"Singh N, Saha L, Kumari P, Singh J, Bhatia A, Banerjee D, Chakrabarti A (2019) Effect of dimethyl fumarate on neuroinflammation and apoptosis in pentylenetetrazol kindling model in rats. Brain Res Bull 144:233\u2013245","journal-title":"Brain Res Bull"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-023-03766-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:25:50Z","timestamp":1715318750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-023-03766-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3766"],"URL":"https:\/\/doi.org\/10.1007\/s12035-023-03766-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3041917\/v1","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"9 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Consejo Superior de Investigaciones Cient\u00edficas (CSIC, Spain) and approved by the Conseller\u00eda de Agricultura, Medio Ambiente, Cambio Climatico y Desarrollo Rural from The <i>Generalitat Valenciana<\/i>. All procedures were approved by the animal committee of the Instituto de Biomedicina de Valencia CSIC, (Permit number IBV-56). All efforts were made to minimize animal suffering.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}